Key points are not available for this paper at this time.
Lawmakers in the US House of Representatives have updated the draft of the Biosecure Act, setting 2032 as the deadline for US drug and biotech companies to break ties with a handful of Chinese "biotechnology companies of concern." The bill, introduced in January , seeks to stop firms that receive federal funds from using select Chinese service companies: the genomics firms BGI, MGI, and Complete Genomics; and WuXi AppTec, a contract drug manufacturer with clients such as Eli Lilly and Company. The bill's latest iteration also adds WuXi AppTec's sister company, WuXi Biologics. The update came after the Biotechnology Innovation Organization (BIO), a trade group, released a survey that highlights the strong dependence of US drug and biotech companies on Chinese contract drug developers and manufacturers and cautions about breaking ties too soon. The survey found that 79% of 124 US companies had at least one contract or product agreement
Aayushi Pratap (Mon,) studied this question.